Royal Bank of Canada
ARTV

Royal Bank of Canada’s Artiva Biotherapeutics ARTV Stock Holding History

Royal Bank of Canada’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
188
-151
-45% -$747 ﹤0.01% 6990
2025
Q4 		$1K Sell
339
-501
-60% -$1.89K ﹤0.01% 7074
2025
Q3 		$3K Sell
840
-280
-25% -$749 ﹤0.01% 6839
2025
Q2 		$2K Buy
1,120
+642
+134% +$1.35K ﹤0.01% 6833
2025
Q1 		$1K Sell
478
-628
-57% -$3.39K ﹤0.01% 6741
2024
Q4 		$11K Sell
1,106
-955
-46% -$11.5K ﹤0.01% 6335
2024
Q3 		$32K Buy
+2,061
New +$23.9K ﹤0.01% 5899

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Royal Bank of Canada's ARTV Position: Q1 2026 in Review

Royal Bank of Canada reduced its Artiva Biotherapeutics (ARTV) stake by 45% in Q1 2026, selling an estimated $747 and leaving 188 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6990.

Royal Bank of Canada first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $32K in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Royal Bank of Canada held 188 shares of Artiva Biotherapeutics worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 151 Artiva Biotherapeutics shares in Q1 2026, an estimated $747.
  • Artiva Biotherapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6990 holding.
  • Royal Bank of Canada first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Royal Bank of Canada's Artiva Biotherapeutics position peaked at $32K in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.